Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

SELLASs Phase 3 REGAL trial of GPS in AML has reached its 80-event trigger, and traders are focused on the pending topline survival results, which the company expects to report in November. The community is largely optimistic and discussing short-squeeze potential, while skeptics emphasize the binary risk and uncertainty of the clinical outcome.

Cerebras quarterly update and stronger revenue outlook, alongside rapid cloud-services growth, fueled a sharp post-results rally; traders also focused on a reported Microsoft deal and potential short covering. Bulls emphasized forward demand and guidance, while skeptics pointed to the larger-than-expected loss, heavy spending, and doubts about whether the rally will hold.

Candels planned prostate-cancer BLA filing was pushed to mid-2027 amid FDA dialogue and assay-refinement work, prompting a sharp selloff and concern about a longer catalyst gap. Traders are split between viewing it as a manageable manufacturing/CMC delay with clinical data intact and questioning managements credibility and the risk of further delays or dilution.

Ciscos quarterly results beat expectations and the company raised its outlook, including its AI infrastructure ambitions. Traders are divided over the muted, volatile reaction: some see profit-taking despite strong results, while others question whether AI demand will translate into durable growth.

A sharp selloff following weaker-than-expected quarterly Anktiva sales and limited management commentary has focused debate on commercial execution, cash needs and potential dilution. Bulls point to the positive BCG-naive trial result, planned FDA filing and label expansion as future growth drivers, while skeptics question whether those developments will translate into faster sales.

Nu Holdings Q3 earnings are driving discussion, with traders weighing strong revenue and profit growth and improved cost efficiency against concerns about credit quality, rising delinquencies, and missed expectations on some metrics. Reactions are split between investors calling the results solid and dip-buying, and skeptics questioning whether growth is coming at the expense of loan performance.

Applied Materials fiscal fourth-quarter results beat expectations and its next-quarter guidance topped estimates, but the shares showed little follow-through, fueling debate over whether the strong report was already priced in. Bulls point to the record quarter and solid outlook, while skeptics cite a muted reaction and post-earnings options volatility as reasons for caution.

CDNL is drawing attention after Q3 results revealed a sharp margin squeeze tied to project cost revisions, prompting the company to withdraw its 2026 outlook; the CFOs planned departure and a postponed acquisition have added to concerns about management and execution. Traders are split between fearing further deterioration and viewing the selloff as excessive, with bullish arguments centering on the companys cash position and an authorizedbut not mandatedshare repurchase program.

Hot inflation data has lifted Treasury yields and Fed rate-hike expectations, while a stronger dollar has pressured gold and driven a sharp GLD selloff. Traders are split between buying the dip and expecting further declines, with some questioning golds safe-haven appeal amid the weakness.

QXOs quarterly results are drawing attention, with traders highlighting improved revenue and margins alongside a newly authorized share-repurchase program. The reaction is mixed: some see the results and buyback as support for the business, while others are frustrated that the stock weakened despite the positive report and point to interest rates and housing-market concerns as headwinds.